Oxford Nanopore Technologies Ltd, the company behind the only portable real-time DNA/RNA sequencer, MinION, has raised $140 million in new investment. Funds were raised from global investors including GIC (Singapore), CCB International (CCBI, China), Hostplus (Australia), and other existing investors.
The funds will be used to support the Company’s next phase of commercial expansion. This includes a new high-volume, high-tech manufacturing facility in Oxford to meet accelerating demand for Oxford Nanopore’s sequencing technology, and growth of the commercial team that already serves more than 70 countries.
The funds raised will also support R&D as Oxford Nanopore expands its suite of nanopore analysis devices. The currently available pocket MinION and desktop GridION are being joined by high-throughput modular sequencing with PromethION and small, single-test sequencing with Flongle.
This expanded range is designed to address all parts of the existing DNA-sequencing market, as well as enabling new applications that can only be performed with a real-time, scalable, long-read technology. For example, Flongle is designed to enable the rapid real-time genetic analysis of infectious diseases, targeted analyses in precision medicine, food and/or water-safety surveillance, and science education. PromethION will enable large-scale, on-demand sequencing of human, plant, or animal genomes.
Oxford Nanopore technology also uniquely enables direct RNA sequencing, providing full-length transcript and viral genome profiling, precise quantification, the ability to identify modified bases in real time, and simplifying workflows.
Oxford Nanopore is headquartered in the UK (Oxford and Cambridge) with a commercial presence in New York, Cambridge (USA), China, Japan, France, and Germany. New headquarters recently opened in Oxford and new operations are now being opened in Shanghai and San Francisco.